Willem Jan van Weelden

The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study

Willem Jan van Weelden, Casper Reijnen, Heidi V.N. Küsters‐Vandevelde et al. · Human Pathology · 2020 · 40 citations · Full text

Medicine, Gynecology, Oncology +13

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

Stephanie Vrede, Willem Jan van Weelden, Nicole C.M. Visser et al. · Gynecologic Oncology · 2021 · 37 citations · Full text

Medicine, Gynecology, Oncology +14

Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study

Willem Jan van Weelden, Casper Reijnen, Florine A. Eggink et al. · European Journal of Cancer · 2020 · 34 citations · Full text

Medicine, Gynecology, Oncology +17

Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer

Stephanie Vrede, Jenneke C. Kasius, Johan Bulten et al. · JAMA Network Open · 2022 · 29 citations · Full text

Medicine, Oncology, Pathology +17

Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer

Stephanie Vrede, Willem Jan van Weelden, Johan Bulten et al. · Gynecologic Oncology · 2024 · 27 citations · Full text

Medicine, Endocrinology, Oncology +16